Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRACR2A | Q9BSW2 | 4/20 | 0.44 |
| ▸ | STIM1 | Q13586 | 2/20 | 0.44 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 5/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | MERTK | Q12866 | 1/20 | 0.41 |
| ▸ | TRPC1 | P48995 | 1/20 | 0.40 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3824262 | 0.85 | SMN1; SMN2 (0.45) | CRACR2ASTIM1ORAI1KMT2ANAMPT | |
| SCHEMBL14117304 | 0.83 | STIM1 (0.48) | CRACR2ASTIM1ORAI1TRPC1TRPC3 | |
| SCHEMBL986498 | 0.80 | STIM1 (0.50) | CRACR2ASTIM1ORAI1NAMPTTRPC1 | |
| SCHEMBL3830830 | 0.80 | STIM1 (0.46) | CRACR2ASTIM1ORAI1TRPC1TRPC3 | |
| SCHEMBL986733 | 0.80 | STIM1 (0.45) | CRACR2ASTIM1ORAI1TRPC1TRPC3 | |
| SCHEMBL3829884 | 0.80 | STIM1 (0.45) | CRACR2ASTIM1ORAI1NAMPTAXL | |
| SCHEMBL985021 | 0.78 | STIM1 (0.53) | CRACR2ASTIM1ORAI1KMT2ATRPC1 | |
| SCHEMBL987530 | 0.78 | TRPV1 (0.43) | CRACR2ASTIM1ORAI1NAMPTTRPC1 | |
| SCHEMBL1781207 | 0.78 | TRPV1 (0.47) | CRACR2ASTIM1ORAI1TRPC1TRPC3 | |
| SCHEMBL615223 | 0.78 | KDM4E (0.43) | CRACR2ASTIM1ORAI1NAMPTTRPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140248299-A1 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-09-04 | — | — | US | claimed |
| US-8729069-B2 | Tetrahydropyridine, tetrahydroazepine, and dihydropyrrole derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-20 | — | — | US | claimed |
| EP-1984337-B1 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2014-04-30 | — | — | EP | claimed |
| US-20110015184-A1 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-01-20 | — | — | US | claimed |
| US-7816535-B2 | such as N-[4-(1,4-dimethyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-2,6-difluoro-benzamide; immunosuppressive agents; allergic disorders, and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2010-10-19 | — | — | US | claimed |
| US-20070249051-A1 | such as N-[4-(1,4-dimethyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-2,6-difluoro-benzamide; immunosuppressive agents; allergic disorders, and immune disorders | SYNTA PHARMACEUTICALS CORP. | 2007-10-25 | — | — | US | claimed |
| US-20140248299-A1 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140248299-A1 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-09-04 | — | — | US | disclosed |
| US-8729069-B2 | Tetrahydropyridine, tetrahydroazepine, and dihydropyrrole derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729069-B2 | Tetrahydropyridine, tetrahydroazepine, and dihydropyrrole derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-20 | — | — | US | disclosed |
| EP-1984337-B1 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2014-04-30 | — | — | EP | disclosed |
| US-20110015184-A1 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20110015184-A1 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-01-20 | — | — | US | disclosed |
| US-7816535-B2 | such as N-[4-(1,4-dimethyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-2,6-difluoro-benzamide; immunosuppressive agents; allergic disorders, and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816535-B2 | such as N-[4-(1,4-dimethyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-2,6-difluoro-benzamide; immunosuppressive agents; allergic disorders, and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816535-B2 | such as N-[4-(1,4-dimethyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-2,6-difluoro-benzamide; immunosuppressive agents; allergic disorders, and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20070249051-A1 | such as N-[4-(1,4-dimethyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-2,6-difluoro-benzamide; immunosuppressive agents; allergic disorders, and immune disorders | SYNTA PHARMACEUTICALS CORP. | 2007-10-25 | — | — | US | disclosed |
| US-20070249051-A1 | such as N-[4-(1,4-dimethyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-2,6-difluoro-benzamide; immunosuppressive agents; allergic disorders, and immune disorders | SYNTA PHARMACEUTICALS CORP. | 2007-10-25 | — | — | US | disclosed |
| US-20070249051-A1 | such as N-[4-(1,4-dimethyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-2,6-difluoro-benzamide; immunosuppressive agents; allergic disorders, and immune disorders | SYNTA PHARMACEUTICALS CORP. | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015184-A1 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR10, CXCL10, CXCR3 | CRACR2A 4029/4885STIM1 1607/4885ORAI1 1772/4885 |
| US-20140248299-A1 | VINYL-PHENYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR10, CXCL10, CXCR3 | CRACR2A 4029/4885STIM1 1607/4885ORAI1 1772/4885 |
| US-20070249051-A1 | such as N-[4-(1,4-dimethyl-1,2,5,6-tetrahydro-pyridin-3-yl)-phenyl]-2,6-difluoro-benzamide; immunosuppressive agents; allergic disorders, and immune disorders | IL4, IL5, IL2 | CRACR2A 4301/4885STIM1 1396/4885ORAI1 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.